Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Bexarotene

Summary

Persistence. It cannot be excluded that bexarotene is persistent, due to the lack of data.

Bioaccumulation. It cannot be excluded that bexarotene bioaccumulates, due to the lack of data.

Toxicity. It cannot be excluded that bexarotene is toxic, due to the lack of data.

Risk. Risk of environmental impact of bexarotene cannot be excluded, due to the lack of environmental toxicity data.

 

Environmental information is missing on fass.se for bexarotene (2024-07-04).

Detailed information

Scientific discussion about Targretin

Scientific discussion about Targretin (bexarotene), Ligand Pharmaceuticals UK Limited, first published: 16/02/2021.

"The Marketing Authorisation Holder states that bexarotene will not be manufactured in the E.U. The expected patient numbers in the E.U. is not anticipated to exceed 1200 patients/annum, therefore it is a low volume compound. Its therapeutic use is not considered to have an immediate effect on the environment."

Author: Health and Medical Care Administration, Region Stockholm